Wall Street Zen cut shares of Caribou Biosciences (NASDAQ:CRBU – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Caribou Biosciences presently has an average rating of “Moderate Buy” and an average target price of $8.50.
Check Out Our Latest Stock Report on CRBU
Caribou Biosciences Stock Performance
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $1.48 million. Sell-side analysts predict that Caribou Biosciences will post -1.64 EPS for the current year.
Institutional Trading of Caribou Biosciences
Several large investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in Caribou Biosciences in the first quarter valued at approximately $61,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Caribou Biosciences by 19.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,442,121 shares of the company’s stock worth $1,317,000 after purchasing an additional 234,052 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock valued at $480,000 after buying an additional 463,391 shares during the period. Pale Fire Capital SE boosted its holdings in shares of Caribou Biosciences by 7.2% during the 1st quarter. Pale Fire Capital SE now owns 786,722 shares of the company’s stock worth $718,000 after buying an additional 52,518 shares in the last quarter. Finally, Aberdeen Group plc raised its stake in Caribou Biosciences by 126.5% during the 1st quarter. Aberdeen Group plc now owns 411,144 shares of the company’s stock worth $375,000 after buying an additional 229,657 shares during the period. 77.51% of the stock is owned by institutional investors.
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Recommended Stories
- Five stocks we like better than Caribou Biosciences
- What is the Shanghai Stock Exchange Composite Index?
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- Consumer Discretionary Stocks Explained
- Alphabet Enters a Bull Market: Is It Time to Buy?
- The Basics of Support and Resistance
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.